Clinical Analysis of Maintenance Therapy with Thalidomine and Bortezomib for Multiple Myeloma.
10.7534/j.issn.1009-2137.2018.06.015
- Author:
Yan-Jie XU
1
;
Bing XIA
1
;
Lu WANG
1
;
Chao-Yu WANG
1
;
Hai-Feng ZHAO
1
;
Hong-Liang YANG
1
;
Xiao-Fang WANG
1
;
Ya-Fei WANG
1
;
Yong YU
1
;
Yi-Zhuo ZHANG
2
Author Information
1. Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjing Municipal Key Laboratory of Cancer Prevention and Therapy, Tianjin Municipal Clinical Research Center for Cancer，Tianjin 300060, China.
2. Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjing Municipal Key Laboratory of Cancer Prevention and Therapy, Tianjin Municipal Clinical Research Center for Cancer，Tianjin 300060, China.E-mail: yizhuozhang111@163.com.
- Publication Type:Journal Article
- MeSH:
Aged;
Antineoplastic Combined Chemotherapy Protocols;
therapeutic use;
Boronic Acids;
Bortezomib;
administration & dosage;
Disease-Free Survival;
Humans;
Multiple Myeloma;
drug therapy;
Pyrazines;
Retrospective Studies;
Thalidomide;
administration & dosage;
Transplantation, Autologous;
Treatment Outcome
- From:
Journal of Experimental Hematology
2018;26(6):1668-1674
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To evaluate the therapeutic effect and adverse reactions of the maintenance therapies with Thalidomine or Bortezomib in the patients with newly diagnosed multiple myeloma (MM), so as to provide a reference for clinical treatment.
METHODS:A retrospective analysis was conducted to compare the progression-free survival (PFS), overall survival (OS) and adverse reaction rate of 23 MM patients received the maintenance therapies of Bortezomib and of 68 MM patients received maintenance therapy of Thalidomine.
RESULTS:The maintenance therapy with Bortezomib could extend the PFS of MM patients as compared with Thalidomine (PFS rate of patients on the maintenance therapy of Bortezomib in 12th, and 24th month was 100%, 88.89%, and that of Thalidomine-treated group was 72.31%, 47.54%). What's more, some specific patients could get better 2-year PFS rate in Bortezomib group than that in Thalidomine group, such as older than 65 years old, after autologous hematopoietic stem cell transplantation(ASCT), having genetic changes, extramedullary lesions, poor renal function, low serum free light chain ratio, high β2-MG, anemia, high LDH, VGPR of induction and consolidation therapy. The OS rate of Bortezomib on 18th, 24th and 30th month was 100%, 88.89%, 80% verus 91.52%,83.63%,72.90% of the group with thalidemide at the same time. As for 2-year OS rate, the Bortezomib group was higher than Thalidomine without statistical differences. However, the patients such as older than 65 years old, poor renal function and with extramedullary lesions, would also get higher 2-year OS rate from Bortezomi. Bortezomib and thalidomide could cause bone marrow suppression, peripheral neuritis and other adverse reactions.
CONCLUSION:The efficacy of maintenance therapy with Bortezomib is superior to thalidomide. As a conclusion, bortezomib is a better option for maintenance therapy of MM patient.
